CRISPR Therapeutics AG CRSP

Healthcare Biotechnology

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem a...

NDAQ:CRSP - Post by User

CRISPR Therapeutics AG

<< Previous

Bullboard Posts

Next >>

(2)
•••

Post by jw1traderon Aug 24, 2022 12:51pm

313 Views

Post# 34917469

Switzerland-based biotechnology leader

portfolio of therapies across a range of disease areas, including treatments for blood disorders, specialized cancers and other rare conditions. With strategic partnerships that include major players such as Bayer AG (BAYRY) and Vertex Pharmaceuticals Inc. (VRTX)

<< Previous

Bullboard Posts

Next >>

A clean technology company on the verge of transformational growth